Effect of Antisecretory Drugs and Nitrates on the Risk of Ulcer Bleeding Associated With Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, and Anticoagulants

Lanas, Angel; García-Rodríguez, Luis A.; Arroyo, Maria T.; Bujanda, Luis; Gomollón, Fernando; Forné, Montserrat; Aleman, Sofía; Nicolas, David; Feu, Faust; González-Pírez, Antonio; Borda, Ana; Castro, Manuel; Poveda, Maria Jose; Arenas, Juan
March 2007
American Journal of Gastroenterology;Mar2007, Vol. 102 Issue 3, p507
Academic Journal
OBJECTIVES: After the withdrawal of some cyclooxygenase-2 (COX-2) selective inhibitors, traditional nonsteroidal anti-inflammatory drug (NSAID) use has increased, but without additional prevention strategies against upper gastrointestinal (GI) complications in many cases. Here, we report the effect of antisecretory drugs and nitrates on the risk of upper GI peptic ulcer bleeding (UGIB) associated with nonselective NSAIDs, aspirin, antiplatelet agents, and anticoagulants. METHODS: This case–control study matched 2,777 consecutive patients with UGIB (confirmed by endoscopy) with 5,532 controls (2:1). Adjusted relative risks (RR) of UGIB are reported. RESULTS: Proton pump inhibitors (PPIs) (RR 0.33, 95% confidence interval [CI] 0.27–0.39), H2-receptor antagonists (H2-RAs) (RR 0.65, 95% CI 0.50–0.85), and nitrates (RR 0.52, 95% CI 0.38–0.70) reduced UGIB risk. PPI use was associated with greater reductions among both traditional NSAID (RR 0.13, 95% CI 0.09–0.19 vs RR 0.30, 95% CI 0.17–0.53 with H2-RAs; RR 0.48, 95% CI 0.19–1.24 with nitrates) and low-dose aspirin users (RR 0.32, 95% CI 0.22–0.51 vs RR 0.40, 95% CI 0.19–0.73 with H2-RA; RR 0.69, 95% CI 0.36–1.04 with nitrates), and among patients taking clopidogrel (RR 0.19, 95% CI 0.07–0.49). For patients taking anticoagulants, use of nitrates, H2-RA, or PPIs was not associated with a significant effect on UGIB risk. CONCLUSION: Antisecretory agent or nitrate treatment is associated with reduced UGIB RR in patients taking NSAID or aspirin. Only PPI therapy was associated with a marked, consistent risk reduction among patients receiving all types of agents (including nonaspirin antiplatelet agents). Protection was not apparent in patients taking anticoagulants.


Related Articles

  • The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. Toshihisa Takeuchi; Kazuhiro Ota; Satoshi Harada; Shoko Edogawa; Yuichi Kojima; Satoshi Tokioka; Eiji Umegaki; Kazuhide Higuchi // BMC Gastroenterology;2013, Vol. 13 Issue 1, p1 

    Background: There is a lack of consensus regarding the risk of postoperative hemorrhage in patients on antithrombotic therapy who undergo endoscopic submucosal dissection (ESD). We examined postoperative bleeding rates and risk factors for postoperative hemorrhage from post-ESD gastric ulcers in...

  • Celecoxib + esomeprazole effective in haemorrhage prevention.  // Reactions Weekly;5/19/2007, Issue 1152, p1 

    The article describes a study of the effectiveness of the combination of the COX 2 inhibitor celecoxib and the proton pump inhibitor (PPI) esomeprazole in preventing recurrent ulcer haemorrhage in high-risk patients. The cumulative incidence of the primary endpoint was 0% in the combined...

  • Use of Physician Education and Computer Alert to Improve Targeted Use of Gastroprotection Among NSAID Users. Coté, Gregory A.; Rice, John P.; Bulsiewicz, William; Norvell, John P.; Christensen, Keri; Bobb, Anne; Postelnick, Michael; Howden, Colin W. // American Journal of Gastroenterology;May2008, Vol. 103 Issue 5, p1097 

    BACKGROUND: Gastrointestinal (GI) hemorrhage accounts for 200–400,000 admissions in the United States annually. Around 50% of patients with bleeding ulcer have used aspirin and/or nonsteroidal anti-inflammatory drugs (NSAIDs). Misoprostol and proton pump inhibitors (PPIs) may reduce...

  • Pharmacologic Options in the Management of Upper Gastrointestinal Bleeding: Focus on the Elderly. Kyaw, Moe; Chan, Francis // Drugs & Aging;May2014, Vol. 31 Issue 5, p349 

    Despite the major advances in the treatment of peptic ulcer disease, its complication in the elderly has increased. This is because of the increasing use of non-steroidal anti-inflammatory drugs, and the high prevalence of Helicobacter pylori infection. The presentation of peptic ulcers in the...

  • Effectiveness of National Provider Prescription of PPI Gastroprotection Among Elderly NSAID Users. Abraham, Neena S.; Hartman, Christine; Castillo, Diana; Richardson, Peter; Smalley, Walter // American Journal of Gastroenterology;Feb2008, Vol. 103 Issue 2, p323 

    OBJECTIVES: Our aim was to quantify the effect of provider adherence on the risk of NSAID-related upper gastrointestinal events (UGIE). METHODS: We identified from national pharmacy records veterans 65 yr prescribed an NSAID, a coxib, or salicylate (>325 mg/day) at any Veterans Affairs (VA)...

  • Peptic Ulcer Disease in Older People. Lockrey, Gregory; Lim, Lucy // Journal of Pharmacy Practice & Research;Mar2011, Vol. 41 Issue 1, p58 

    Peptic ulcer disease is a common disorder that affects millions of people worldwide. When complications occur, peptic ulcer disease can have a major impact on quality of life and on the utilisation of the health system. Understanding the causative roles of Helicobacterpylori and non-steroidal...

  • Bleeding Peptic Ulcer in the Elderly. Zullo, Angelo; Hassan, Cesare; Campo, Salvatore M. A.; Morini, Sergio // Drugs & Aging;2007, Vol. 24 Issue 10, p815 

    Peptic ulcer bleeding is a frequent and dramatic event with both a high mortality rate and a substantial cost for healthcare systems worldwide. It has been found that age is an independent predisposing factor for gastrointestinal bleeding, with the risk increasing significantly in individuals...

  • COX-2 inhibitor no safer than naproxen and PPI.  // Journal of Family Practice;Mar2006, Vol. 55 Issue 3, p192 

    The article discusses on the study that determines which is safer between celecoxib and naproxen taken with a proton pump inhibitor in treating patients with previous peptic ulcer in Hong Kong, China. Celecoxib was given to patients who were at high risk for persistent occurrence of peptic ulcer...

  • Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002. Hermansson, Michael; Ekedahl, Anders; Ranstam, Jonas; Zilling, Thomas // BMC Gastroenterology;2009, Vol. 9, Special section p1 

    Background: Despite a decreasing incidence of peptic ulcer disease, most previous studies report a stabile incidence of ulcer complications. We wanted to investigate the incidence of peptic ulcer complications in Sweden before and after the introduction of the proton pump inhibitors (PPI) in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics